- Home
- DOCN vs PRAX Comparison
DOCN vs PRAX Comparison
Compare DOCN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCN | PRAX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.0B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DOCN | PRAX |
|---|---|---|
| Price | $48.93 | $286.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $47.58 | ★ $373.79 |
| AVG Volume (30 Days) | ★ 1.5M | 790.5K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 201.90 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $863,962,000.00 | $7,463,000.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $18.85 | $12,467.71 |
| P/E Ratio | $18.24 | ★ N/A |
| Revenue Growth | 14.20 | ★ 364.98 |
| 52 Week Low | $25.45 | $26.70 |
| 52 Week High | $52.20 | $317.72 |
Technical Indicators
Market Signals| Indicator | DOCN | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.68 | 63.90 |
| Support Level | $47.85 | $285.95 |
| Resistance Level | $51.90 | $317.72 |
| Average True Range (ATR) | 1.74 | 12.78 |
| MACD | -0.03 | -1.09 |
| Stochastic Oscillator | 83.54 | 43.76 |
Price Performance
Historical ComparisonAbout DOCN DigitalOcean Holdings Inc.
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.